MANE sentiment intelligence

Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?

Tone

Positive 66/100

Event

Market update

Published

19 Jun 2026 16:24

Source

Market source

Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $138

Jefferies has reiterated its Buy rating on Veradermics (MANE.US) and maintained its target price at $138. This indicates the firm's continued positive outlook on the company's stock performance.

Tone

Positive 75/100

Event

Analyst action

Published

16 Jun 2026 14:39

Source

Moomoo

Veradermics to Present at Upcoming June Investor Conferences

Veradermics, Incorporated announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. CEO Reid Waldman, M.D., and CCO Mark Neuman

Tone

Positive 75/100

Event

Market update

Published

28 May 2026 20:10

Source

Business Wire

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics, Incorporated announced that positive topline results from its Phase 2/3 ‘302’ Study of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, will be presented at the 2026 World Congress for Hair Research. The company believes VDPHL01 could be

Tone

Positive 74/100

Event

Earnings

Published

27 May 2026 14:41

Source

BioSpace

Veradermics to present hair loss drug trial data on Friday

Veradermics, Incorporated (NYSE:MANE) is set to present positive topline results from its Phase 2/3 Study 302 of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, at the 2026 World Congress for Hair Research on Friday, May 30, 2026. The company previo

Tone

Positive 70/100

Event

Earnings

Published

27 May 2026 11:41

Source

Investing.com

Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026

Veradermics (NYSE: MANE) is highlighted as one of the best-performing NYSE stocks in 2026, despite reporting a net loss of $27.2 million in Q1 2026 due to increased R&D and G&A expenses for its lead clinical asset. The company achieved a significant milestone with positive Phase

Tone

Positive 72/100

Event

Market update

Published

20 May 2026 23:02

Source

Insider Monkey

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Incorporated (NYSE: MANE) announced its first quarter 2026 financial results, highlighting positive topline data from its Phase 2/3 Study ‘302’ for VDPHL01, an oral treatment for pattern hair loss. The company successfully upsized IPO and follow-on financing generate

Tone

Positive 71/100

Event

Earnings

Published

20 May 2026 10:09

Source

Business Wire

Veradermics (NYSE:MANE) - Earnings & Revenue Performance

Veradermics (NYSE:MANE) has reported a significant decline in earnings, with an average annual rate of -154.3%, despite the Pharmaceuticals industry seeing a 9.1% annual growth. The company, however, has recently announced positive Phase 2/3 results for its oral hair-loss candida

Tone

Positive 70/100

Event

Earnings

Published

16 May 2026 08:10

Source

Simply Wall Street

MANE Stock Price, Quote & Chart | VERADERMICS INC (NYSE:MANE)

This article provides an overview of VERADERMICS INC (NYSE:MANE) stock, including its current price, performance, and key statistics. It also details the company's technical and fundamental analysis ratings from ChartMill, its earnings history, and analyst forecasts. The company

Tone

Positive 64/100

Event

Earnings

Published

15 May 2026 08:40

Source

ChartMill

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

Veradermics, Incorporated (NYSE: MANE) announced two E-poster presentations at the 2026 Music City SCALE Symposium on their investigational drug VDPHL01 for pattern hair loss. The presentations will detail comparative analyses of VDPHL01's Phase 2 results against existing minoxid

Tone

Positive 71/100

Event

Regulatory and legal

Published

14 May 2026 11:38

Source

Business Wire

Veradermics (NYSE:MANE) - Stock Analysis

Veradermics (NYSE:MANE) is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic and aesthetic conditions, currently specializing in an oral hair loss program. The company's stock is trading significantly below its estimated fair value, with

Tone

Positive 75/100

Event

Market update

Published

14 May 2026 07:39

Source

Simply Wall Street

Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock

Veradermics (NYSE:MANE) has reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential new FDA-approved oral treatment. The company also announced recent substantial funding for its programs. The stock has seen sign

Tone

Positive 76/100

Event

Earnings

Published

14 May 2026 06:38

Source

Simply Wall Street

[10-Q] Veradermics, Inc Quarterly Earnings Report

Veradermics, Inc. (NYSE: MANE) reported a net loss of $27.2 million for Q1 2026, driven by increased investment in late-stage dermatology programs, with R&D expenses rising to $20.9 million. The company significantly strengthened its balance sheet after a February 2026 IPO, which

Tone

Positive 61/100

Event

Earnings

Published

12 May 2026 20:40

Source

Stock Titan

Veradermics (NYSE: MANE) boosts cash with $766.8M raise, advances VDPHL01

Veradermics reported a wider net loss of $27.2 million in Q1 2026 due to increased R&D and G&A spending as it accelerates the development of its lead hair-loss drug, VDPHL01. The company successfully raised $766.8 million through an upsized IPO and follow-on offerings, extending

Tone

Positive 71/100

Event

Balance sheet

Published

12 May 2026 12:39

Source

Stock Titan

Citi Remains Bullish on Veradermics, Incorporated (MANE)

Citi has reiterated its "Buy" rating and increased its price target on Veradermics, Incorporated (MANE) to $120 following positive Phase 2/3 trial results for its VDPHL01 drug in male pattern hair loss. The company's proprietary extended-release oral minoxidil formulation showed

Tone

Positive 87/100

Event

Analyst action

Published

10 May 2026 19:12

Source

Insider Monkey

Is It Too Late To Consider Veradermics (MANE) After A 186% Year To Date Surge?

Veradermics (MANE) has seen a significant 186% year-to-date surge, closing at US$107.85. A Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 71.8%, with an estimated intrinsic value of $382.79 per share, despite projecting ongoing free cash flow l

Tone

Positive 71/100

Event

Balance sheet

Published

10 May 2026 05:38

Source

Simply Wall Street

VDPHL01 hair-loss data and $212.9M capital raise for Veradermics (NYSE: MANE)

Tone

Positive 66/100

Event

Market update

Published

27 Apr 2026 07:00

Source

Stock Titan

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case

Tone

Positive 66/100

Event

Earnings

Published

09 Dec 2025 08:00

Source

simplywall.st